New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
Published By: Datamonitor
May 2009
R313-51599
Online Download $5,700.00
Global Site License $14,250.00
Description
With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
Scope- Overview of ongoing trends affecting R&D and how these will shape Pharma in the future
- R&D Insight from Big Pharma industry executives
- Analysis into Pharma's evolving R&D portfolio between 2006 and 2009, in addition to examination of pipeline M&A and collaborative deals
- Case studies of innovative strategies used to maximize R&D productivity
Highlights- GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development as of March 2009. In terms of volume growth Genentech's pipeline grew the most in terms of percentage points, almost doubling (up 95%).
- Over the period 200609, the average growth per therapy area was 9.4%. In terms of percentage points, the therapy area experiencing the largest growth in pipeline candidates was ophthalmology, while cardiovascular pipelines saw the largest decline, indicative of Pharma's shift towards niche markets and personalized medicines.
- The number of pipeline deals made during 200608 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with many companies going bankrupt, this will affect Big Pharma in the longer term, which is increasingly downsizing internal research becoming ever reliant on external sources.
Reasons to Purchase- Identify R&D trends in today's pharmaceutical market, and how these affect productivity and return on investment
- Understand how a diverse range of strategies can improve R&D productivity and output, and identify how these can best be implemented
- Gain insight into how to optimize R&D processes and increase the chance of clinical, and ultimately commercial success
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the report
- Methodology for primary and secondary research
- Primary research
- Secondary research
- Key findings
- CHAPTER 2 OVERVIEW OF TODAY'S R&D LANDSCAPE
- Current barriers to R&D optimization
- How are pharma companies improving R&D?
- Rivals move to collaborate on R&D
- Enlight Biosciences: a partnership dedicated to technological innovation in R&D
- Companies must be careful not to stifle innovation through M&A
- Two key types of restructuring are available to Pharma
- Refocusing R&D onto biologics will increase efficiency
- CHAPTER 3 ANALYSIS OF MEDTRACK PIPELINE AND DEALS DATABASES
- Product pipelines grow while deal making activity declines
- Analysis of pipeline candidates by therapy area and indication indicate an increased focus on niche markets
- The big four tumors are the most popular indications for solid tumors
- Molecular targeted therapies are leading a paradigm shift in oncology
- Antibacterial, antifungal and antiviral pipelines all demonstrate strong growth
- Novel pipeline antibacterial drugs target niche markets
- Antifungal drug discovery is driven by new patient groups
- CNS continues to be a thriving market despite generic competition
- Fibromyalgia drug development drives growth in pipeline drugs for pain
- Antidepressant drug development drives the psychiatry pipeline forward
- Low levels of innovation hampers the growth of the cardiovascular market
- Ophthalmology had the largest percentage increase in number of drug candidates in clinical development
- Substance abuse saw a steep rise in Phase I drugs, but a decline in other stages of development
- Majority of Big Pharma have expanded their pipeline portfolios since 2006
- Genentech and Bristol-Myers Squibb have shown a significant jump in pipeline candidates
- Genentech's innovative approach spurs an enviable pipeline
- Bristol-Myers Squibb's strong pipeline is attributed to its externalization strategy
- Wyeth, GlaxoSmithKline and Johnson & Johnson saw a decline in their number of pipeline candidates
- Wyeth is experiencing a decline in number of drug candidates due to discontinuations
- GlaxoSmithKline must increase its R&D productivity to sustain future growth
- Johnson & Johnson needs to bolster its early and mid-stage pipeline
- Daiichi Sankyo boosts its early-stage pipeline through externalizations
- Recent mergers will sharpen R&D structure
- Pfizer acquired Wyeth in an effort to diversify its pipeline
- Merck & Co's purchase of Schering-Plough provides R&D synergy and the addition of new therapy areas
- Roche acquired the remaining stake in Genentech to foster R&D in areas of high growth
- Early-stage co-development deals remain the most popular deal type
- Early-stage partnerships are the most popular R&D deal type, but have also seen the steepest decline in recent years
- Co-development deals are most common among earlier-stage companies as well as the top 50 pharma companies
- CHAPTER 4 BIBLIOGRAPHY
- Publications and online articles
- Datamonitor resources
- APPENDIX
- List of Tables
- Table 1: Most popular targets in for drugs in development, 2009
- List of Figures
- Figure 1: The R&D process is failing somewhere between initial innovation and market approval
- Figure 2: Reasons why pipeline drug candidates are dropped, 2009
- Figure 3: Niche, specialty care markets offer Pharma the greatest growth potential
- Figure 4: Restructuring Big Pharma R&D operations to increase productivity
- Figure 5: Biologics will sharpen the focus of the R&D pipeline
- Figure 6: Biologics are changing the emphasis of the value chain
- Figure 7: The greatest number of pipeline candidates are in preclinical and Phase II development, this corresponds to the stages showing the greatest deal activity, 2006-Q1 2009
- Figure 8: Number of US licensing deals valued at $0-50m entered into by the top 20 pharma companies, Q1 2006-Q3 2008
- Figure 9: Change (%) in number of pipeline candidates, Q1 2009 versus 2006
- Figure 10: Pipeline candidates by therapy area and indication, 2006-Q1 2009
- Figure 11: Change in number of pipeline deals by therapy area, 2008 versus 2006
- Figure 12: Number of pipeline candidates versus deals according to therapy area, 2006-Q1 2009
- Figure 13: Level of R&D interest and unmet need for four solid tumors, 2008
- Figure 14: Clinical unmet needs for the main cardiovascular indications
- Figure 15: Vaccines have high entry barriers for generic companies
- Figure 16: Number of pipeline candidates (preclinical and Phase I-III) and number of deals for the top 10 pharma companies, 2006-Q1 2009
- Figure 17: Change (%) in number of pipeline candidates, Q1 2009 versus 2006
- Figure 18: Origins of Bristol-Myers Squibb's product portfolio (2008) and selected key products
- Figure 19: How externalization is supplementing Daiichi Sankyo's oncology pipeline
- Figure 20: Pfizer, Wyeth and combined Pfizer-Wyeth molecule type and therapy area configurations (% of Rx sales), 2008
- Figure 21: Merck & Co, Schering-Plough and combined Merck-Schering-Plough molecule type configuration (% of Rx sales), 2008
- Figure 22: Trends in sources and partners for pipeline drug deals in the pharma industry, 2006-08
- Figure 23: Trends in the source: partner mix for pipeline drug deal-making, 2006-08
- Figure 24: The most common pipeline deal types (2006-08) have been co-development deals although these are now declining
- Figure 25: Top 10 pipeline drug deal types by partner: source mix, 2006-08
- Figure 26: Trends in number of pipeline candidates according to development stage, 2006 - Q1 09
- Figure 27: Trends in number of deals according to development stage, 2006-08
|
Order Form * Please reference product number R313-51599 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
